NX001

The kidney is one of the few human organs that can repair itself after injury. Dr. F. Gary Toback, the founding scientist of NephRx discovered several kidney specific growth factors that hold high promise for the repair and regeneration of kidney cells. Growth factors are protein messengers that can stimulate dormant cells to initiate DNA synthesis and subsequently start the division and multiplication process (mitosis).

In the United States there are over 115,000 hospitalized patients that develop acute kidney injury (AKI) each year.  The cost to treat each case of AKI exceeds $10,000 per patient, which translates to a total cost of over $1 billion per year to the U.S. Healthcare System. The mortality rate is very high and ranges from 42% to 88%. No cure exists and patients are put on dialysis to "rest" the kidney, correct metabolic imbalances and wait for kidney function to return spontaneously. Currently, there are no treatments for acute renal failure other than dialysis and resting the kidney, therefore, no competitive data is available.

NephRx has identified a well-defined patient population for initial clinical trials, which will avoid problems complicating previous trials of potential ARF therapeutics, thus increasing chances for success.